BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sirexatamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sirexatamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05761951-3424@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sirexatamab: Phase 2 readout est. (NCT05761951)
DESCRIPTION:Sirexatamab\, phase 2.\nStudy: Phase 2 Study Evaluating the Eff
 icacy of the Combination of DKN-01 (DKK1 Inhibitor\, Leap Therapeutics) an
 d Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Canc
 er\nEstimated primary completion: 31 January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sirexatamab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05761951
URL:https://assetmemo.bio/drug/sirexatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
